Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study

Tumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients with glioblastoma. This phase 2 PANOVA study was conducted to examine the combination of TTFields plus chemotherapy in patients with pancreatic ductal...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Ročník 19; číslo 1; s. 64 - 72
Hlavní autori:	Rivera, Fernando, Benavides, Manuel, Gallego, Javier, Guillen-Ponce, Carmen, Lopez-Martin, José, Küng, Marc
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland Elsevier B.V 01.01.2019 Elsevier Limited
Predmet:	Adenocarcinoma Aged Aged, 80 and over Albumins - administration & dosage Albumins - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Cancer therapies Cell adhesion & migration Chemotherapy Combined Modality Therapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Electric fields Electric Stimulation Therapy Female Gemcitabine Glioblastoma Humans Male Medical equipment Metastases Metastasis Middle Aged Nab-paclitaxel Neutropenia Paclitaxel Paclitaxel - administration & dosage Paclitaxel - therapeutic use Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - therapy PANOVA Patients Skin Survival Toxicity Tumor treating fields Israel PANOVA Tumor treating fields Gemcitabine Pancreatic cancer Nab-paclitaxel
ISSN:	1424-3903, 1424-3911, 1424-3911
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Tumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients with glioblastoma. This phase 2 PANOVA study was conducted to examine the combination of TTFields plus chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Forty patients with newly-diagnosed, locally advanced or metastatic PDAC received continuous TTFields (150 KHz for ≥18 h/day) plus gemcitabine (1000 mg/m2), or gemcitabine plus nab-paclitaxel (125 mg/m2). The primary endpoint was safety and secondary endpoints included compliance to TTFields, progression-free survival (PFS), and overall survival (OS). Seventeen patients (85%) in each cohort reported Grade ≥3 adverse events (AEs). No increase in serious AEs (SAEs) was observed compared to that anticipated with systemic chemotherapy alone. Twenty-one patients reported TTFields-related skin toxicity, of which 7 were Grade 3; all resolved following temporary reduction of daily TTFields usage. No TTFields-related SAEs were reported. Compliance to TTFields was 68–78% of the recommended average daily use in both cohorts. Median PFS was 8.3 months (95% CI 4.3, 10.3) and median OS was 14.9 months (95% CI 6.2, NA) in the TTFields + gemcitabine cohort. In the TTFields + gemcitabine + nab-paclitaxel cohort, the median PFS was 12.7 months (95% CI 5.4, NA); median OS has not been reached. The PANOVA trial demonstrated that the combination of TTFields and systemic chemotherapy is safe and tolerable in patients with advanced PDAC. Based on the safety and preliminary efficacy results of this phase 2 study, a randomized phase 3 study (PANOVA-3) is underway.
AbstractList	Tumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients with glioblastoma. This phase 2 PANOVA study was conducted to examine the combination of TTFields plus chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).BACKGROUNDTumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients with glioblastoma. This phase 2 PANOVA study was conducted to examine the combination of TTFields plus chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).Forty patients with newly-diagnosed, locally advanced or metastatic PDAC received continuous TTFields (150 KHz for ≥18 h/day) plus gemcitabine (1000 mg/m2), or gemcitabine plus nab-paclitaxel (125 mg/m2). The primary endpoint was safety and secondary endpoints included compliance to TTFields, progression-free survival (PFS), and overall survival (OS).METHODSForty patients with newly-diagnosed, locally advanced or metastatic PDAC received continuous TTFields (150 KHz for ≥18 h/day) plus gemcitabine (1000 mg/m2), or gemcitabine plus nab-paclitaxel (125 mg/m2). The primary endpoint was safety and secondary endpoints included compliance to TTFields, progression-free survival (PFS), and overall survival (OS).Seventeen patients (85%) in each cohort reported Grade ≥3 adverse events (AEs). No increase in serious AEs (SAEs) was observed compared to that anticipated with systemic chemotherapy alone. Twenty-one patients reported TTFields-related skin toxicity, of which 7 were Grade 3; all resolved following temporary reduction of daily TTFields usage. No TTFields-related SAEs were reported. Compliance to TTFields was 68-78% of the recommended average daily use in both cohorts. Median PFS was 8.3 months (95% CI 4.3, 10.3) and median OS was 14.9 months (95% CI 6.2, NA) in the TTFields + gemcitabine cohort. In the TTFields + gemcitabine + nab-paclitaxel cohort, the median PFS was 12.7 months (95% CI 5.4, NA); median OS has not been reached.RESULTSSeventeen patients (85%) in each cohort reported Grade ≥3 adverse events (AEs). No increase in serious AEs (SAEs) was observed compared to that anticipated with systemic chemotherapy alone. Twenty-one patients reported TTFields-related skin toxicity, of which 7 were Grade 3; all resolved following temporary reduction of daily TTFields usage. No TTFields-related SAEs were reported. Compliance to TTFields was 68-78% of the recommended average daily use in both cohorts. Median PFS was 8.3 months (95% CI 4.3, 10.3) and median OS was 14.9 months (95% CI 6.2, NA) in the TTFields + gemcitabine cohort. In the TTFields + gemcitabine + nab-paclitaxel cohort, the median PFS was 12.7 months (95% CI 5.4, NA); median OS has not been reached.The PANOVA trial demonstrated that the combination of TTFields and systemic chemotherapy is safe and tolerable in patients with advanced PDAC. Based on the safety and preliminary efficacy results of this phase 2 study, a randomized phase 3 study (PANOVA-3) is underway.CONCLUSIONThe PANOVA trial demonstrated that the combination of TTFields and systemic chemotherapy is safe and tolerable in patients with advanced PDAC. Based on the safety and preliminary efficacy results of this phase 2 study, a randomized phase 3 study (PANOVA-3) is underway. Tumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients with glioblastoma. This phase 2 PANOVA study was conducted to examine the combination of TTFields plus chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Forty patients with newly-diagnosed, locally advanced or metastatic PDAC received continuous TTFields (150 KHz for ≥18 h/day) plus gemcitabine (1000 mg/m2), or gemcitabine plus nab-paclitaxel (125 mg/m2). The primary endpoint was safety and secondary endpoints included compliance to TTFields, progression-free survival (PFS), and overall survival (OS). Seventeen patients (85%) in each cohort reported Grade ≥3 adverse events (AEs). No increase in serious AEs (SAEs) was observed compared to that anticipated with systemic chemotherapy alone. Twenty-one patients reported TTFields-related skin toxicity, of which 7 were Grade 3; all resolved following temporary reduction of daily TTFields usage. No TTFields-related SAEs were reported. Compliance to TTFields was 68–78% of the recommended average daily use in both cohorts. Median PFS was 8.3 months (95% CI 4.3, 10.3) and median OS was 14.9 months (95% CI 6.2, NA) in the TTFields + gemcitabine cohort. In the TTFields + gemcitabine + nab-paclitaxel cohort, the median PFS was 12.7 months (95% CI 5.4, NA); median OS has not been reached. The PANOVA trial demonstrated that the combination of TTFields and systemic chemotherapy is safe and tolerable in patients with advanced PDAC. Based on the safety and preliminary efficacy results of this phase 2 study, a randomized phase 3 study (PANOVA-3) is underway. BackgroundTumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients with glioblastoma. This phase 2 PANOVA study was conducted to examine the combination of TTFields plus chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).MethodsForty patients with newly-diagnosed, locally advanced or metastatic PDAC received continuous TTFields (150 KHz for ≥18 h/day) plus gemcitabine (1000 mg/m2), or gemcitabine plus nab-paclitaxel (125 mg/m2). The primary endpoint was safety and secondary endpoints included compliance to TTFields, progression-free survival (PFS), and overall survival (OS).ResultsSeventeen patients (85%) in each cohort reported Grade ≥3 adverse events (AEs). No increase in serious AEs (SAEs) was observed compared to that anticipated with systemic chemotherapy alone. Twenty-one patients reported TTFields-related skin toxicity, of which 7 were Grade 3; all resolved following temporary reduction of daily TTFields usage. No TTFields-related SAEs were reported. Compliance to TTFields was 68–78% of the recommended average daily use in both cohorts. Median PFS was 8.3 months (95% CI 4.3, 10.3) and median OS was 14.9 months (95% CI 6.2, NA) in the TTFields + gemcitabine cohort. In the TTFields + gemcitabine + nab-paclitaxel cohort, the median PFS was 12.7 months (95% CI 5.4, NA); median OS has not been reached.ConclusionThe PANOVA trial demonstrated that the combination of TTFields and systemic chemotherapy is safe and tolerable in patients with advanced PDAC. Based on the safety and preliminary efficacy results of this phase 2 study, a randomized phase 3 study (PANOVA-3) is underway. Tumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients with glioblastoma. This phase 2 PANOVA study was conducted to examine the combination of TTFields plus chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Forty patients with newly-diagnosed, locally advanced or metastatic PDAC received continuous TTFields (150 KHz for ≥18 h/day) plus gemcitabine (1000 mg/m ), or gemcitabine plus nab-paclitaxel (125 mg/m ). The primary endpoint was safety and secondary endpoints included compliance to TTFields, progression-free survival (PFS), and overall survival (OS). Seventeen patients (85%) in each cohort reported Grade ≥3 adverse events (AEs). No increase in serious AEs (SAEs) was observed compared to that anticipated with systemic chemotherapy alone. Twenty-one patients reported TTFields-related skin toxicity, of which 7 were Grade 3; all resolved following temporary reduction of daily TTFields usage. No TTFields-related SAEs were reported. Compliance to TTFields was 68-78% of the recommended average daily use in both cohorts. Median PFS was 8.3 months (95% CI 4.3, 10.3) and median OS was 14.9 months (95% CI 6.2, NA) in the TTFields + gemcitabine cohort. In the TTFields + gemcitabine + nab-paclitaxel cohort, the median PFS was 12.7 months (95% CI 5.4, NA); median OS has not been reached. The PANOVA trial demonstrated that the combination of TTFields and systemic chemotherapy is safe and tolerable in patients with advanced PDAC. Based on the safety and preliminary efficacy results of this phase 2 study, a randomized phase 3 study (PANOVA-3) is underway.
Author	Gallego, Javier Lopez-Martin, José Küng, Marc Rivera, Fernando Guillen-Ponce, Carmen Benavides, Manuel
Author_xml	– sequence: 1 givenname: Fernando surname: Rivera fullname: Rivera, Fernando email: fernando.rivera@scsalud.es organization: Hospital Universitario Marqués de Valdecilla, Santander, Spain – sequence: 2 givenname: Manuel surname: Benavides fullname: Benavides, Manuel email: manuel.benavides.sspa@juntadeandalucia.es organization: Hospital Universitario Regional y Virgen de la Victoria, Andalucia, Spain – sequence: 3 givenname: Javier surname: Gallego fullname: Gallego, Javier email: gallego.jav@gva.es organization: Plazas Hospital General Universitario de Elche, Elche, Spain – sequence: 4 givenname: Carmen orcidid: 0000-0002-3594-1084 surname: Guillen-Ponce fullname: Guillen-Ponce, Carmen email: carmen.guillen@salud.madrid.org organization: Ramon y Cajal, Madrid, Spain – sequence: 5 givenname: José surname: Lopez-Martin fullname: Lopez-Martin, José email: jalopez.hdoc@salud.madrid.org organization: Hospital 12 de Octubre, Madrid, Spain – sequence: 6 givenname: Marc surname: Küng fullname: Küng, Marc email: marc.kueng@h-fr.ch organization: Hôpital Fribourgeois, Fribourg, Switzerland
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/30396819$$D View this record in MEDLINE/PubMed
BookMark	eNqFkc1u1DAUhS1URH_gAdggS2zYZLAdJ5nAalTxJ1UUocLW8jg3HQ-OndoOMK_BE3PDlArNosgL-1595-r6nFNy5IMHQp5ytuCM1y-3i1H7hWB8ifWCMfmAnHApZFG2nB_dvVl5TE5T2jImBOftI3JcsrKtl7w9Ib-upiFEmiPobP017S24LlHrqQnD2nrsBk9_2Lyh1zAYmzU2gaLk33J0U6Jer4tRG4fNn-DmEbid-TPYUINPiK_oZ0iTy4mGnuYN0E-rj5dfV3Tc6ARU0JSnbveYPOy1S_Dk9j4jX96-uTp_X1xcvvtwvroojGxkLqpKNCB413cNsJZXlWwbaCpgHP8mgUPVVqWBVuiq4awzTW3Kai2XtWiMKZeyPCMv9nPHGG4mSFkNNhlwTnsIU1KCo02sboRA9PkBug1T9LgdUvVSzqdE6tktNa0H6NQY7aDjTv11GwG-B0wMKUXo7xDO1Jyo2ir0TM2Jzi1MFDXNgWZ2fU4lR23dvcrXeyWgid8tRJWMBYyhsxFMVl2w96rbAzUm663R7hvs_qP9DV-ZzRs
CitedBy_id	crossref_primary_10_1016_j_tranon_2021_101296 crossref_primary_10_3322_caac_70035 crossref_primary_10_1634_theoncologist_2017_0603 crossref_primary_10_3390_cancers15133340 crossref_primary_10_2478_raon_2023_0044 crossref_primary_10_3389_fmicb_2023_1296558 crossref_primary_10_1016_j_bbcan_2022_188808 crossref_primary_10_3390_neurolint13020015 crossref_primary_10_1093_oncolo_oyae227 crossref_primary_10_1038_s41420_022_01206_y crossref_primary_10_3389_fncel_2023_1133984 crossref_primary_10_1002_cam4_7350 crossref_primary_10_1007_s11864_025_01320_w crossref_primary_10_1016_j_critrevonc_2021_103535 crossref_primary_10_3390_cancers14061568 crossref_primary_10_1016_j_bioelechem_2021_107881 crossref_primary_10_1007_s40042_022_00575_y crossref_primary_10_3390_ijms26094445 crossref_primary_10_1080_09553002_2020_1837984 crossref_primary_10_1007_s40042_025_01319_4 crossref_primary_10_4103_jcrt_jcrt_819_22 crossref_primary_10_3389_fonc_2022_1055366 crossref_primary_10_1007_s11864_020_00773_5 crossref_primary_10_1016_j_hoc_2022_07_003 crossref_primary_10_1007_s12094_024_03551_z crossref_primary_10_1089_bioe_2020_0051 crossref_primary_10_3390_cancers15030636 crossref_primary_10_3389_fonc_2021_670809 crossref_primary_10_3389_fneur_2024_1413236 crossref_primary_10_1016_j_ejca_2025_115306 crossref_primary_10_1088_1361_6560_ab33c6 crossref_primary_10_3390_cancers13215510 crossref_primary_10_3390_pharmaceutics11110574 crossref_primary_10_3390_ijms24055016 crossref_primary_10_1007_s12672_025_02861_0 crossref_primary_10_1200_JCO_25_00746 crossref_primary_10_1158_0008_5472_CAN_22_0887 crossref_primary_10_1186_s12876_025_03807_0 crossref_primary_10_3390_cancers14082020 crossref_primary_10_3892_ol_2022_13458 crossref_primary_10_1063_5_0008462 crossref_primary_10_1080_09553002_2020_1838658 crossref_primary_10_1038_s41416_020_01136_5 crossref_primary_10_1109_TBME_2024_3383818 crossref_primary_10_3389_fonc_2025_1520504 crossref_primary_10_1016_S1470_2045_23_00344_3 crossref_primary_10_1080_02688697_2021_1886242 crossref_primary_10_1200_JCO_25_01040 crossref_primary_10_3390_jfb16050160 crossref_primary_10_3389_fonc_2021_738801 crossref_primary_10_3389_fimmu_2022_1017400 crossref_primary_10_1002_anbr_202200143
Cites_doi	10.1158/0008-5472.CAN-04-0083 10.1001/jama.2017.18718 10.1038/srep18046 10.1016/j.ejca.2012.04.011 10.1016/j.lungcan.2013.06.025 10.1038/nrclinonc.2015.53 10.1073/pnas.0702916104 10.1053/j.seminoncol.2014.03.011 10.1001/jama.2016.4324 10.1517/13543784.2011.583236 10.1016/j.ygyno.2018.07.018 10.1056/NEJMoa1304369 10.1371/journal.pone.0125269 10.1016/j.pan.2013.11.009 10.1056/NEJMoa1011923 10.1001/jamaoncol.2016.0585
ContentType	Journal Article
Copyright	2018 The Author(s) 2018 IAP and EPC Copyright © 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved. Copyright Elsevier Limited Jan 2019
Copyright_xml	– notice: 2018 The Author(s) – notice: 2018 IAP and EPC – notice: Copyright © 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved. – notice: Copyright Elsevier Limited Jan 2019
DBID	6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. NAPCQ 7X8
DOI	10.1016/j.pan.2018.10.004
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Anatomy & Physiology
EISSN	1424-3911
EndPage	72
ExternalDocumentID	30396819 10_1016_j_pan_2018_10_004 S1424390318306987
Genre	Clinical Trial, Phase II Journal Article
GeographicLocations	Israel
GeographicLocations_xml	– name: Israel
GroupedDBID	--- --K -RU .1- .FO 0R~ 0~B 123 1P~ 29O 36B 4.4 457 53G 8UI AAEDT AAEDW AAIKJ AAJMK AAKOC AALRI AAQFI AAQXK AATTM AAXKI AAXUO AAYIC AAYWO ABBTS ABJNI ABLJU ABMAC ABWCG ABWVN ACDAQ ACGFO ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEBSH AEIPS AENEX AEUPX AEVXI AEYAO AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BELOY BKEYQ BKOJK BNPGV BPHCQ BVXVI CAG COF CS3 CYUIP DU5 E0A EBS EFJIC EFKBS EFLBG EJD EMB EMOBN FB. FDB FEDTE FGOYB FYGXN GBLVA HVGLF HZ~ KOM KUZGX M41 N9A O1H O9- OC. ON0 P2P PQQKQ PROAC R2- ROL SEL SPCBC SSH SSZ SV3 T5K UJ6 WOW Z5R 3V. 6I. 7RV AACTN AAFTH AAIAV ABLVK ADPAM AFCTW AFKWA AGZHU ALXNB AZPMC BENPR RIG RKO AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. NAPCQ 7X8
ID	FETCH-LOGICAL-c474t-5527e21dfd7e09155497e75e013964e1e5953ce92a5710dc76c35b48627cc3843
ISICitedReferencesCount	74
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000456089400011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1424-3903 1424-3911
IngestDate	Sun Sep 28 02:40:12 EDT 2025 Mon Oct 06 17:12:35 EDT 2025 Thu Apr 03 07:08:06 EDT 2025 Wed Oct 29 21:14:49 EDT 2025 Tue Nov 18 22:23:06 EST 2025 Fri Feb 23 02:29:08 EST 2024 Tue Oct 14 19:25:52 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	PANOVA Tumor treating fields Gemcitabine Pancreatic cancer Nab-paclitaxel
Language	English
License	This is an open access article under the CC BY-NC-ND license. Copyright © 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c474t-5527e21dfd7e09155497e75e013964e1e5953ce92a5710dc76c35b48627cc3843
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23
ORCID	0000-0002-3594-1084
OpenAccessLink	https://dx.doi.org/10.1016/j.pan.2018.10.004
PMID	30396819
PQID	2168484843
PQPubID	25450
PageCount	9
ParticipantIDs	proquest_miscellaneous_2130306722 proquest_journals_2168484843 pubmed_primary_30396819 crossref_primary_10_1016_j_pan_2018_10_004 crossref_citationtrail_10_1016_j_pan_2018_10_004 elsevier_sciencedirect_doi_10_1016_j_pan_2018_10_004 elsevier_clinicalkey_doi_10_1016_j_pan_2018_10_004
PublicationCentury	2000
PublicationDate	January 2019 2019-01-00 2019-Jan 20190101
PublicationDateYYYYMMDD	2019-01-01
PublicationDate_xml	– month: 01 year: 2019 text: January 2019
PublicationDecade	2010
PublicationPlace	Switzerland
PublicationPlace_xml	– name: Switzerland – name: Philadelphia
PublicationTitle	Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
PublicationTitleAlternate	Pancreatology
PublicationYear	2019
Publisher	Elsevier B.V Elsevier Limited
Publisher_xml	– name: Elsevier B.V – name: Elsevier Limited
References	Giladi, Schneiderman, Voloshin, Porat, Munster, Blat (bib10) 2015 Dec 11; 5 Stupp, Taillibert, Kanner, Read, Steinberg, Lhermitte (bib6) 2017 Dec 19; 318 Stupp, Wong, Kanner, Steinberg, Engelhard, Heidecke (bib7) 2012 Sep; 48 Mehta, Gondi, Ahluwalia, Brown (bib19) 2018 Lacouture, Davis, Elzinga, Butowski, Tran, Villano (bib20) 2014 Jun; 41 Jemal, Bray, Center, Ferlay, Ward, Forman (bib1) 2011; 61 Kirson, Dbalý, Tovarys, Vymazal, Soustiel, Itzhaki (bib11) 2007 Jun 12; 104 Giladi, Schneiderman, Porat, Munster, Itzhaki, Mordechovich (bib14) 2014 Jan–Feb; 14 Siegel, Miller, Jemal (bib2) 2016; 66 Pless, Weinberg (bib13) 2011 Aug; 20 Von Hoff, Ervin, Arena, Chiorean, Infante, Moore (bib4) 2013 Oct 31; 369 Hammel, Huguet, van Laethem, Goldstein, Glimelius, Artru (bib21) 2016 May; 315 Rahib, Fleshman, Matrisian, Berlin (bib22) 2016 Sep; 2 Kirson, Gurvich, Schneiderman, Dekel, Itzhaki, Wasserman (bib8) 2004 May; 64 Gera, Yang, Holtzman, Lee, Wong, Swanson (bib9) 2015; 10 Conroy, Desseigne, Ychou, Bouché, Guimbaud, Bécouarn (bib3) 2011; 364 Schneiderman, Giladi, Porat, Munster, Kirson, Weinberg (bib12) 2014 Sep; 74 Wenger, Yesharim, Naveh, Hershkovich, Weinberg, Bomzon (bib15) 2017 Jun; 28 Garrido-Laguna, Hidalgo (bib5) 2015 Jun; 12 Grosso, Mądrzak, Ramlau, Perez, Crinò, Chella (bib18) 2017 Jan; 12 Vergote, von Moos, Manso, Van Nieuwenhuysen, Concin, Sessa (bib17) 2018 Pless, Droege, von Moos, Salzberg, Betticher (bib16) 2013 Sep; 81 Grosso (10.1016/j.pan.2018.10.004_bib18) 2017; 12 Lacouture (10.1016/j.pan.2018.10.004_bib20) 2014; 41 Pless (10.1016/j.pan.2018.10.004_bib13) 2011; 20 Rahib (10.1016/j.pan.2018.10.004_bib22) 2016; 2 Gera (10.1016/j.pan.2018.10.004_bib9) 2015; 10 Mehta (10.1016/j.pan.2018.10.004_bib19) 2018 Conroy (10.1016/j.pan.2018.10.004_bib3) 2011; 364 Stupp (10.1016/j.pan.2018.10.004_bib6) 2017; 318 Von Hoff (10.1016/j.pan.2018.10.004_bib4) 2013; 369 Stupp (10.1016/j.pan.2018.10.004_bib7) 2012; 48 Kirson (10.1016/j.pan.2018.10.004_bib8) 2004; 64 Kirson (10.1016/j.pan.2018.10.004_bib11) 2007; 104 Pless (10.1016/j.pan.2018.10.004_bib16) 2013; 81 Vergote (10.1016/j.pan.2018.10.004_bib17) 2018 Giladi (10.1016/j.pan.2018.10.004_bib10) 2015; 5 Wenger (10.1016/j.pan.2018.10.004_bib15) 2017; 28 Hammel (10.1016/j.pan.2018.10.004_bib21) 2016; 315 Garrido-Laguna (10.1016/j.pan.2018.10.004_bib5) 2015; 12 Giladi (10.1016/j.pan.2018.10.004_bib14) 2014; 14 Schneiderman (10.1016/j.pan.2018.10.004_bib12) 2014; 74 Jemal (10.1016/j.pan.2018.10.004_bib1) 2011; 61 Siegel (10.1016/j.pan.2018.10.004_bib2) 2016; 66
References_xml	– volume: 315 start-page: 1844 year: 2016 May end-page: 1853 ident: bib21 article-title: Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 Months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial publication-title: J Am Med Assoc – volume: 364 start-page: 1817 year: 2011 end-page: 1825 ident: bib3 article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer publication-title: N Engl J Med – volume: 66 start-page: 7 year: 2016 end-page: 30 ident: bib2 article-title: Cancer statistics publication-title: Ca - Cancer J Clin – volume: 10 year: 2015 ident: bib9 article-title: Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit publication-title: PLoS One – volume: 104 start-page: 10152 year: 2007 Jun 12 end-page: 10157 ident: bib11 article-title: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors publication-title: Proc Natl Acad Sci U S A – volume: 74 year: 2014 Sep ident: bib12 article-title: TTFields reduce cancer cell clonogenic potential through abnormal chromosome segregation during mitosis publication-title: Cancer Res – volume: 12 start-page: S329 year: 2017 Jan ident: bib18 article-title: OA22.01 STELLAR - interim results of a phase 2 trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma publication-title: J Thorac Oncol – year: 2018 ident: bib17 article-title: Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study publication-title: Gynecol Oncol – volume: 41 start-page: S1 year: 2014 Jun end-page: S14 ident: bib20 article-title: Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma publication-title: Semin Oncol – volume: 64 start-page: 3288 year: 2004 May end-page: 3295 ident: bib8 article-title: Disruption of cancer cell replication by alternating electric fields publication-title: Cancer Res – volume: 12 start-page: 319 year: 2015 Jun end-page: 334 ident: bib5 article-title: Pancreatic cancer: from state-of-the-art treatments to promising novel therapies publication-title: Nat Rev Clin Oncol – volume: 2 start-page: 1209 year: 2016 Sep end-page: 1216 ident: bib22 article-title: Evaluation of pancreatic cancer clinical trials and benchmarks for clinically meaningful future trials: a systematic review publication-title: JAMA Oncol – year: 2018 ident: bib19 article-title: TTFields and radiosurgery for 1 to 10 brain metastases from NSCLC in the phase III METIS study publication-title: Proceedings of the 109th annual meeting of the american association for cancer research; 2018 apr 14-18; Chicago, Illinois. Philadelphia (PA) – volume: 48 start-page: 2192 year: 2012 Sep end-page: 2202 ident: bib7 article-title: NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality publication-title: Eur J Canc – volume: 28 year: 2017 Jun ident: bib15 article-title: A simulation-based study on the distribution of TTFields in the body when treating pancreatic cancer publication-title: Ann Oncol – volume: 61 start-page: 69 year: 2011 end-page: 90 ident: bib1 article-title: Global cancer statistics publication-title: Ca - Cancer J Clin – volume: 81 start-page: 445 year: 2013 Sep end-page: 450 ident: bib16 article-title: A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer publication-title: Lung Canc – volume: 369 start-page: 1691 year: 2013 Oct 31 end-page: 1703 ident: bib4 article-title: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine publication-title: N Engl J Med – volume: 14 start-page: 54 year: 2014 Jan–Feb end-page: 63 ident: bib14 article-title: Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields publication-title: Pancreatology – volume: 20 start-page: 1099 year: 2011 Aug end-page: 1106 ident: bib13 article-title: Tumor treating fields: concept, evidence and future publication-title: Expet Opin Invest Drugs – volume: 5 start-page: 18046 year: 2015 Dec 11 ident: bib10 article-title: Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells publication-title: Sci Rep – volume: 318 start-page: 2306 year: 2017 Dec 19 end-page: 2316 ident: bib6 article-title: Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial publication-title: J Am Med Assoc – volume: 64 start-page: 3288 issue: 9 year: 2004 ident: 10.1016/j.pan.2018.10.004_bib8 article-title: Disruption of cancer cell replication by alternating electric fields publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-0083 – volume: 318 start-page: 2306 issue: 23 year: 2017 ident: 10.1016/j.pan.2018.10.004_bib6 article-title: Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial publication-title: J Am Med Assoc doi: 10.1001/jama.2017.18718 – volume: 5 start-page: 18046 year: 2015 ident: 10.1016/j.pan.2018.10.004_bib10 article-title: Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells publication-title: Sci Rep doi: 10.1038/srep18046 – volume: 48 start-page: 2192 issue: 14 year: 2012 ident: 10.1016/j.pan.2018.10.004_bib7 article-title: NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality publication-title: Eur J Canc doi: 10.1016/j.ejca.2012.04.011 – volume: 81 start-page: 445 issue: 3 year: 2013 ident: 10.1016/j.pan.2018.10.004_bib16 article-title: A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer publication-title: Lung Canc doi: 10.1016/j.lungcan.2013.06.025 – volume: 12 start-page: 319 issue: 6 year: 2015 ident: 10.1016/j.pan.2018.10.004_bib5 article-title: Pancreatic cancer: from state-of-the-art treatments to promising novel therapies publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2015.53 – volume: 61 start-page: 69 issue: 2 year: 2011 ident: 10.1016/j.pan.2018.10.004_bib1 article-title: Global cancer statistics publication-title: Ca - Cancer J Clin – volume: 104 start-page: 10152 issue: 24 year: 2007 ident: 10.1016/j.pan.2018.10.004_bib11 article-title: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0702916104 – volume: 41 start-page: S1 issue: Suppl 4 year: 2014 ident: 10.1016/j.pan.2018.10.004_bib20 article-title: Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2014.03.011 – volume: 315 start-page: 1844 issue: 17 year: 2016 ident: 10.1016/j.pan.2018.10.004_bib21 article-title: Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 Months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial publication-title: J Am Med Assoc doi: 10.1001/jama.2016.4324 – volume: 20 start-page: 1099 issue: 8 year: 2011 ident: 10.1016/j.pan.2018.10.004_bib13 article-title: Tumor treating fields: concept, evidence and future publication-title: Expet Opin Invest Drugs doi: 10.1517/13543784.2011.583236 – year: 2018 ident: 10.1016/j.pan.2018.10.004_bib17 article-title: Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2018.07.018 – volume: 74 issue: suppl 19 year: 2014 ident: 10.1016/j.pan.2018.10.004_bib12 article-title: TTFields reduce cancer cell clonogenic potential through abnormal chromosome segregation during mitosis publication-title: Cancer Res – volume: 369 start-page: 1691 issue: 18 year: 2013 ident: 10.1016/j.pan.2018.10.004_bib4 article-title: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine publication-title: N Engl J Med doi: 10.1056/NEJMoa1304369 – volume: 66 start-page: 7 issue: 1 year: 2016 ident: 10.1016/j.pan.2018.10.004_bib2 article-title: Cancer statistics publication-title: Ca - Cancer J Clin – volume: 12 start-page: S329 issue: 1 year: 2017 ident: 10.1016/j.pan.2018.10.004_bib18 article-title: OA22.01 STELLAR - interim results of a phase 2 trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma publication-title: J Thorac Oncol – volume: 10 issue: 5 year: 2015 ident: 10.1016/j.pan.2018.10.004_bib9 article-title: Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit publication-title: PLoS One doi: 10.1371/journal.pone.0125269 – volume: 28 issue: suppl 3 year: 2017 ident: 10.1016/j.pan.2018.10.004_bib15 article-title: A simulation-based study on the distribution of TTFields in the body when treating pancreatic cancer publication-title: Ann Oncol – volume: 14 start-page: 54 issue: 1 year: 2014 ident: 10.1016/j.pan.2018.10.004_bib14 article-title: Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields publication-title: Pancreatology doi: 10.1016/j.pan.2013.11.009 – volume: 364 start-page: 1817 issue: 19 year: 2011 ident: 10.1016/j.pan.2018.10.004_bib3 article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1011923 – volume: 2 start-page: 1209 issue: 9 year: 2016 ident: 10.1016/j.pan.2018.10.004_bib22 article-title: Evaluation of pancreatic cancer clinical trials and benchmarks for clinically meaningful future trials: a systematic review publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.0585 – year: 2018 ident: 10.1016/j.pan.2018.10.004_bib19 article-title: TTFields and radiosurgery for 1 to 10 brain metastases from NSCLC in the phase III METIS study
SSID	ssj0022119
Score	2.4690359
Snippet	Tumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients with... BackgroundTumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	64
SubjectTerms	Adenocarcinoma Aged Aged, 80 and over Albumins - administration & dosage Albumins - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Cancer therapies Cell adhesion & migration Chemotherapy Combined Modality Therapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Electric fields Electric Stimulation Therapy Female Gemcitabine Glioblastoma Humans Male Medical equipment Metastases Metastasis Middle Aged Nab-paclitaxel Neutropenia Paclitaxel Paclitaxel - administration & dosage Paclitaxel - therapeutic use Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - therapy PANOVA Patients Skin Survival Toxicity Tumor treating fields
Title	Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1424390318306987 https://dx.doi.org/10.1016/j.pan.2018.10.004 https://www.ncbi.nlm.nih.gov/pubmed/30396819 https://www.proquest.com/docview/2168484843 https://www.proquest.com/docview/2130306722
Volume	19
WOSCitedRecordID	wos000456089400011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1424-3911 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022119 issn: 1424-3903 databaseCode: AIEXJ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELb2wYELAhbYwrIyEnCgSpU4TpxwC2h5SZRKLKi3KHXcpas2rdpmVf4Gv5gZ20lTqi4PCVWKGqd2ks4XzyPfjAl56nu5GuYZdwauDB0OPgTMg3nohL5kbpCBSs2HerEJ0e1G_X7c29vnVS7M1VgURbRaxbP_KmpoA2Fj6uxfiLseFBrgOwgdtiB22P6Z4MsJMge1MYgsSaSoadIrnAzcYCNwHX69UBM5WmYDNDShS3N3NsbCrdnAAZcay3iv1FjzzQEjemCJbDGp5oZPtyjHhhKCVmwv6X76mrRn30A_tlmjfq01gXt2DFP8aVcZizWps4pWNoCkiXubw4CdnPQwxNHpdNrPglc6lN2plk_XVbpBktpStqHzaR2JUAUS-818-TErSlWzTt7iSjMX5uVUhhZEfaDEHMrC6WHWpyXOTGxWnY2hYNrWRgxlO7lH6wLOuOPHrpl_VbPN6odKgcRbD4rRBqY-u7UrzApFWxrLBE8uOyBAJBpGHc015Gv1XJMmP-PJ8XpgFnbDOBL75JCJIIa5_DB5f9b_UAcasGqfzqqzN1C9zde8xl9OtMse2-Vvabvr_Da5ZR0mmhig3yF7qrhLjhKAxXTynT6nmsKsQXBEfmjs0wr71GCfjgrawD5F7NMG2Cl0ae4i9ukm9nGINfapwf5LapFPp0MKeKUG-VQjnzKqkX-PfHlzdv76nWMXHXEkF3zpYEVCxbx8mAvl4uIJPBZKBApdpZArTwVx4EsVsywA4zyXIpR-MOBRyISUfsT9--SgmBbqmFDh8aEA_S14DF6Jn2WRirOMSTdkDCZOr0Xc6q9Ppa3IjwvDjNOKenmZwr2lKC1sAmm1yIu6y8yUo7nux6ySZ1rlWYNlkAL0ruvE607WCDfG9e-6nVSASe1ksUiZF0YcP36LPKkPg_7Cl5JZoaYl_sbXYQvGWuSBAVp9Z3AkDsFlefhv1_SI3Fw_7CfkYDkv1WNyQ14tR4v5KdkX_ejUPjo_Ad9zISY
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor+treating+fields+in+combination+with+gemcitabine+or+gemcitabine+plus+nab-paclitaxel+in+pancreatic+cancer%3A+Results+of+the+PANOVA+phase+2+study&rft.jtitle=Pancreatology+%3A+official+journal+of+the+International+Association+of+Pancreatology+%28IAP%29+...+%5Bet+al.%5D&rft.au=Rivera%2C+Fernando&rft.au=Benavides%2C+Manuel&rft.au=Gallego%2C+Javier&rft.au=Guillen-Ponce%2C+Carmen&rft.date=2019-01-01&rft.pub=Elsevier+B.V&rft.issn=1424-3903&rft.eissn=1424-3911&rft.volume=19&rft.issue=1&rft.spage=64&rft.epage=72&rft_id=info:doi/10.1016%2Fj.pan.2018.10.004&rft.externalDocID=S1424390318306987
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1424-3903&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1424-3903&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1424-3903&client=summon